N-alkylated aminoacyl sulfamoyladenosines as potential inhibitors of aminoacylation reactions and microcin C analogues containing D-amino acids

PLoS One. 2013 Nov 4;8(11):e79234. doi: 10.1371/journal.pone.0079234. eCollection 2013.

Abstract

Microcin C analogues were recently envisaged as important compounds for the development of novel antibiotics. Two issues that may pose problems to these potential antibiotics are possible acquisition of resistance through acetylation and in vivo instability of the peptide chain. N-methylated aminoacyl sulfamoyladenosines were synthesized to investigate their potential as aminoacyl tRNA synthetase inhibitors and to establish whether these N-alkylated analogues would escape the natural inactivation mechanism via acetylation of the alpha amine. It was shown however, that these compounds are not able to effectively inhibit their respective aminoacyl tRNA synthetase. In addition, we showed that (D)-aspartyl-sulfamoyladenosine (i.e. with a (D)-configuration for the aspartyl moiety), is a potent inhibitor of aspartyl tRNA synthetase. However, we also showed that the inhibitory effect of (D)- aspartyl-sulfamoyladenosine is relatively short-lasting. Microcin C analogues with (D)-amino acids throughout from positions two to six proved inactive. They were shown to be resistant against metabolism by the different peptidases and therefore not able to release the active moiety. This observation could not be reversed by incorporation of (L)-amino acids at position six, showing that none of the available peptidases exhibit endopeptidase activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / analogs & derivatives
  • Adenosine / chemistry
  • Adenosine / pharmacology
  • Amino Acids / chemistry*
  • Amino Acyl-tRNA Synthetases / antagonists & inhibitors*
  • Amino Acyl-tRNA Synthetases / chemistry
  • Amino Acyl-tRNA Synthetases / metabolism
  • Aminoacylation / drug effects
  • Anti-Bacterial Agents / chemistry
  • Anti-Bacterial Agents / pharmacology
  • Aspartate-tRNA Ligase / antagonists & inhibitors
  • Aspartate-tRNA Ligase / chemistry
  • Aspartate-tRNA Ligase / metabolism
  • Bacteriocins / chemistry*
  • Bacteriocins / pharmacology*
  • Biocatalysis / drug effects
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology
  • Escherichia coli / drug effects
  • Escherichia coli / genetics
  • Escherichia coli / metabolism
  • Escherichia coli Proteins / antagonists & inhibitors
  • Escherichia coli Proteins / chemistry
  • Escherichia coli Proteins / metabolism
  • Molecular Structure
  • Sulfonamides / chemistry
  • Sulfonamides / pharmacology
  • Time Factors

Substances

  • Amino Acids
  • Anti-Bacterial Agents
  • Bacteriocins
  • Enzyme Inhibitors
  • Escherichia coli Proteins
  • Sulfonamides
  • microcin
  • Amino Acyl-tRNA Synthetases
  • Aspartate-tRNA Ligase
  • Adenosine

Grants and funding

GV was recipient of a Belgian IWT fellowship (SB81117). MS was made possible by the Hercules Foundation of the Flemish Government (grant 20100225-7). KS was supported by a Russian Academy of Sciences Presidium Nanotechnology Program grant. Bharat Gadakh received an Erasmus Mundus External Cooperation Window lot 13 fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.